Full clinical trial disclosure needed: expert

Silversides, Ann
July 2006
CMAJ: Canadian Medical Association Journal;7/18/2006, Vol. 175 Issue 2, p140
Academic Journal
The article relates the claims of Andreas Laupacis of the Canadian Expert Drug Advisory Committee that legislation is required to force pharmaceutical companies to disclose clinical trial information to Canadians. Laupacis noted that pharmaceutical companies do not make complete information about the original trial protocols and outcomes available. The group makes recommendations to Common Drug Review members on the effectiveness and cost effectiveness of new prescription drugs.


Related Articles

  • Lighting the Trial Disclosure Path. Agres, Ted // Drug Discovery & Development;Aug2005, Vol. 8 Issue 8, p14 

    Focuses on the efforts of pharmaceutical companies to prove that they are complying with established guidelines to disclose results of clinical trials in the U.S. Support of the companies on the proposed registration of clinical trials or the dissemination of trial results; Proposal of the...

  • Reality Check: Is It Newsworthy? Durand, Michael // Pharmaceutical Executive;Apr2003 Supplement, Vol. 23, p18 

    Discusses the roles of in-house and consultant public relations (PR) professionals in making sound and timely decisions about publicizing pharmaceutical companies' clinical trial results in the United States. Goals of releasing news; Rules for reporting clinical trials data; PR strategy. ...

  • The Good and the Bad. Duttge, Willow // Pharmaceutical Executive;Apr2005, Vol. 25 Issue 4, p114 

    Reports on the need for clinical trial transparency within the pharmaceutical industry in the U.S. Disclosure of drug information for customer knowledge; Proposal of clinical trial registries in scientific journals; Effort of companies to balance the public's need to know with the industry's...

  • Disclosure of information on clinical trials.  // WHO Drug Information;2005, Vol. 19 Issue 2, p129 

    Announces the principles of disclosure of clinical trial information through clinical trial registries and databases developed by the research-based pharmaceutical industry. Associations involved in the principles of disclosure of clinical trial information; Demonstration of the innovative...

  • Congress Wants Data to Be Free. Agres, Ted // Drug Discovery & Development;Nov2004, Vol. 7 Issue 11, p14 

    Reports that the U.S. Congress is pressuring the pharmaceutical industry to disclose all information from company-sponsored clinical trials. Agreement among major drug companies to voluntarily make public their clinical trial results either on their own web site or through an industry database...

  • GSK Settles with New York. Tolchin, Elizabeth // Drug Discovery & Development;Nov2004, Vol. 7 Issue 11, p23 

    Reports on the settlement between the GlaxoSmithKline PLC and the New York Attorney General's office over charges that the drug company misrepresented Paxil and its safety for use in children and adolescents with depression. Claim that GlaxoSmithKline has agreed to post results of all its...

  • Trial Data on the Hot Seat. Lammers, Paul // Drug Discovery & Development;Oct2005, Vol. 8 Issue 10, p60 

    The article focuses on the growing pressure on pharmaceutical companies to disclose information on their trials and results in the U.S. At the core of the controversy is a general sense that drug manufacturers only provide selective disclosure of clinical trials results, resulting in increased...

  • Glaxo Opens Door to Research Data.  // MondayMorning;10/15/2012, Vol. 20 Issue 39, p1 

    The article offers information on GlaxoSmithKline PLC (GSK), a pharmaceutical company, which is setting a new policy to review the information from its studies with scientists. It mentions that GSK was fined by three billion dollars for fraud related to hiding safety issues. It adds that the new...

  • Lilly to Establish Public Clinical Trial Registry.  // Chemical Market Reporter;8/9/2004, Vol. 266 Issue 5, p4 

    Reports that Eli Lilly & Co. will establish a public clinical trial registry for all its marketed products. Information that will be included in the registry.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics